Transgene SA (EPA: TNG)
France
· Delayed Price · Currency is EUR
0.778
+0.002 (0.26%)
Nov 20, 2024, 5:35 PM CET
Transgene Revenue
Transgene had revenue of 3.36M EUR in the half year ending June 30, 2024, a decrease of -44.85%. This brings the company's revenue in the last twelve months to 6.49M, down -28.00% year-over-year. In the year 2023, Transgene had annual revenue of 7.90M, down -23.63%.
Revenue (ttm)
6.49M
Revenue Growth
-28.00%
P/S Ratio
12.12
Revenue / Employee
44.48K
Employees
141
Market Cap
102.69M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7.90M | -2.44M | -23.63% |
Dec 31, 2022 | 10.34M | -6.90M | -40.00% |
Dec 31, 2021 | 17.24M | 7.67M | 80.08% |
Dec 31, 2020 | 9.57M | -3.72M | -28.00% |
Dec 31, 2019 | 13.30M | 6.21M | 87.69% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sanofi | 48.45B |
EssilorLuxottica Société anonyme | 25.83B |
Sartorius Stedim Biotech S.A. | 2.74B |
bioMérieux S.A. | 3.81B |
Ipsen S.A. | 3.44B |
Eurofins Scientific SE | 6.72B |
Virbac SA | 1.34B |
Ramsay Générale de Santé SA | 5.01B |
Transgene News
- 2 months ago - Half Year 2024 Transgene SA Earnings Call Transcript - GuruFocus
- 1 year ago - Transgene SA (TRGNF) Q2 2023 Earnings Call Transcript - Seeking Alpha
- 1 year ago - Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio - Business Wire
- 2 years ago - Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration - Business Wire
- 2 years ago - Transgene and BioInvent Joint Paper on BT-001 Wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022 - Business Wire
- 2 years ago - BioInvent and Transgene Joint Paper on BT-001 Wins JITC Best Oncolytic and Local Immunotherapy Paper Award for 2022 - Accesswire
- 2 years ago - Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers - Business Wire
- 2 years ago - R&D Day: Presentations to Highlight Transgene's Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data - Business Wire